RT Journal Article
SR Electronic
T1 EP1013 Overview of non-epithelial ovarian tumours: incidence and survival in the netherlands
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP A534
OP A534
DO 10.1136/ijgc-2019-ESGO.1057
VO 29
IS Suppl 4
A1 OL van der Hel
A1 M Timmermans
A1 AM van Altena
A1 RFPM Kruitwagen
A1 BFM Slangen
A1 GS Sonke
A1 KK van de Vijver
A1 MA van der Aa
YR 2019
UL http://ijgc.bmj.com/content/29/Suppl_4/A534.1.abstract
AB Introduction/Background About 5% of ovarian tumours have a non-epithelial histology, including germ cell tumours (GCTs), sex cord-stromal tumours (SCSTs), and sarcomas. Since the rarity of these non-epithelial ovarian tumours and the scarcity of population-based studies, the aim of this population-based study is to describe trends in incidence, treatment, and survival of these women in the Netherlands.Methodology All Dutch women diagnosed with non-epithelial ovarian malignant tumours between 1989 and 2015 were identified from the Netherlands Cancer Registry. Demographics, tumour characteristics, and initial treatment were collected and overall survival was analysed.Results A total of 1258 women were diagnosed with non-epithelial ovarian tumours in the Netherlands, including 752 GCTs (60%), 341 SCSTs (27%), and 165 sarcomas (13%). The European age standardized incidence rate (ESR) was 0.4 per 100,000 persons per year for GCTs, 0.2 for SCSTs and 0.1 for sarcomas. Approximately 97% of patients underwent surgical resection for the primary tumour, whereas 31% received systemic treatment and 3% radiotherapy. Five-year overall survival improved for all histologic subtypes between the late 1980’s until 2015: GCTs from 73% to 88% (p=0.03) SCSTs from 64% to 81% (p=0.57) and sarcomas from 20% to 29% (p=0.14).Conclusion Malignant GCTs and SCSTs are rare and its incidence did not significantly change during the last decades. They have a good prognosis which also improved slightly. Women with primary sarcomas of the ovary are extremely rare and still have a poor prognosis.Disclosure Nothing to disclose.